TEM
$46.96-1.78 (-3.65%)
Tempus AI, Inc.
Recent News
H.C. Wainwright Raises Tempus AI (TEM) Price Target to $95
Tempus AI, Inc. (NASDAQ:TEM) is among the 10 Best New AI Stocks to Buy. On March 9, H.C. Wainwright analyst Yi Chen raised the firm’s price target on Tempus AI, Inc. (NASDAQ:TEM) to $95 from $89 while maintaining a Buy rating. The analyst highlighted the company’s expanding network of strategic partnerships, including collaborations with Merck & Co., […]
Tempus AI Pediatric Leukemia Registry Deepens Oncology Data And Patient Reach
Tempus AI and Blood Cancer United have launched an AI powered real world registry for pediatric acute myeloid leukemia. The registry is designed to centralize clinical and patient reported data to support research and empower affected families. Tempus AI is deploying its olivia platform to help patients and caregivers engage with their health information and care teams. Tempus AI, listed as NasdaqGS:TEM, is building this registry at a time when the stock trades around $48.69 per share. The...
Is It Time To Reassess Tempus AI (TEM) After Recent Share Price Weakness?
Wondering if Tempus AI is attractively priced or just riding hype? This article walks you through what the numbers actually say about its current valuation. The stock closed at US$50.84, with a 0.1% decline over 7 days, a 2.1% decline over 30 days, and an 18.5% decline year to date, though it is up 11.2% over the past year. Recent coverage of Tempus AI has focused on its role in applying artificial intelligence to healthcare data. This has kept investor attention on how the business model...
Is Tempus AI (TEM) The Best AI Healthcare Stock in Cathie Wood’s Portfolio?
Tempus AI (NASDAQ:TEM) is one of the Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. Tempus AI (NASDAQ:TEM) uses AI to analyze and process large datasets to find patterns that help doctors treat patients more efficiently. ARK increased its stake in Tempus AI (NASDAQ:TEM) by 6% in the fourth quarter to about $446.28 million. […]
Tempus AI Expands Clinical Validation of AI-Powered Cancer Diagnostics
TEM advances precision oncology as studies validate IPS, PurIST and xF+ diagnostics, highlighting stronger guidance for cancer therapy and biomarker detection.